Immunosuppressive Drugs Market Report 2020-2030
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 4 segmentations of the Immunosuppressive Drugs Market, with forecasts for 5 Drug Classes, 5 Applications, 2 Route of Administrations Type, & 3 Distribution Channels and each forecasted at a global and regional level.
By Drug Class
- Antibodies
- Calcineurin Inhibitor
- mTOR Inhibitor
- Corticosteroids
- Others
- Autoimmune Diseases
- Rheumatoid Arthritis
- Multiple Sclerosis
- Psoriasis
- Crohn’s Disease
- Others
- Organ Transplant
- Oral Drugs
- Intravenous Drugs
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1. Introduction
- 1.1.1. What are Immunosuppressive Drugs?
- 1.1.2. Side Effects of Immunosuppressive Drugs?
- 1.1.3. What are Autoimmune Diseases?
- 1.1.4. What is Transplantation
- 1.1.5. What is Organ Rejection?
- 1.1.6. Immunosuppressive Drugs for Organ Transplant
- 1.1.7. Types of Immunosuppressive Drugs
- 1.2. Global Immunosuppressive Drugs Market Segmentation
- 1.3. Why You Should Read This Report
- 1.4. What This Report Delivers
- 1.5. Key Questions Answered By This Analytical Report Include:
- 1.6. Who is This Report For?
- 1.7. Methodology
- 1.7.1. COVID-19 Impact: Recovery Scenarios
- 1.7.2. Market Evaluation & Forecasting Methodology
- 1.7.3. Market Size Estimation
- 1.8. Frequently Asked Questions (FAQ)
- 1.9. Associated Visiongain Reports
- 1.10. About Visiongain
- 2. Executive Summary of the Immunosuppressive Drugs Market
- 3. Market Overview of the Immunosuppressive Drugs Market
- 3.1. Market Dynamics
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing Prevalence of Autoimmune Diseases
- 3.1.1.2. Rising Number of Organ Transplant Procedures
- 3.1.1.3. Launch of New Immunosuppressive Drugs
- 3.1.2. Market Restraints
- 3.1.2.1. Adverse-Effects and Risks of Immunosuppressive Drugs
- 3.1.2.2. High Cost of Immunosuppressant Drugs
- 3.1.2.3. Product Recall
- 3.1.3. Market Opportunities
- 3.1.3.1. Large Amount of R&D Investment by Pharmaceutical Companies
- 3.1.3.2. Government and NGO’s Initiatives for Organ Donation Awareness Programmes
- 3.1.3.3. Presence of Reimbursement Policies for Immunosuppressive Drugs
- 3.1.4. Market Challenges
- 3.1.4.1. Transplant Rejection
- 3.1.4.2. Shortage of Organ Donors
- 3.1.5. SWOT Analysis
- 3.1.5.1. Strengths
- 3.1.5.1.1. Promising Candidates in R&D
- 3.1.5.1.2. Unmet Clinical Need
- 3.1.5.2. Weaknesses
- 3.1.5.2.1. High Cost of Immunosuppressive Drugs
- 3.1.5.2.2. Generic Drugs Competition
- 3.1.5.3. Opportunities
- 3.1.5.3.1. Increasing Mergers & Acquisitions and Collaborations
- 3.1.5.3.2. Large Amount of R&D Investment
- 3.1.5.4. Threats
- 3.1.5.4.1. Ethical and Cultural Issues
- 3.1.6. Porter’s Five Forces Analysis
- 3.1.6.1. Competitive Rivalry
- 3.1.6.2. Supplier Power
- 3.1.6.3. Buyer Power
- 3.1.6.4. Threat of Substitution
- 3.1.6.5. Threat of New Entry
- 3.1.7. PEST Analysis
- 3.1.7.1. Political Issues: Stringent Government Regulations
- 3.1.7.2. Economic Pressures Raise Demand for Cost Effective Drugs
- 3.1.7.3. Social Factors: Increase of Disposable Income
- 3.1.7.4. Technological Factors: Adoption of High-end Technologies by Pharmaceutical and Biotechnology Companies
- 4. Global Immunosuppressive Drugs Market Size Forecast 2020-2030 by Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 4.1. Market Overview
- 4.2. Global Immunosuppressive Drugs Market: COVID-19 Recovery Forecasts (V,U, W, L) 2020-2030
- 4.2.1. "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
- 4.2.2. "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
- 4.2.3. "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
- 4.2.4. "L" Shaped Recovery - Rapid Decline - Then Slow Growth
- 4.3. Antibodies
- 4.3.1. Significantly decreased the occurrence of episodes of acute rejection
- 4.4. Calcineurin Inhibitor
- 4.4.1. Growing adoption for the treatment of patients with organ transplant
- 4.5. mTOR Inhibitor
- 4.5.1. Some of the commonly used mTOR inhibitor drugs are rapamycin, sirolimus, temsirolimus, and everolimus
- 4.6. Corticosteroids
- 4.6.1. Effectiveness in a wide range of immune and inflammatory conditions
- 4.7. Other Drug Classes
- 4.7.1. Rising investment in R&D by pharmaceutical and biopharmaceutical companies boosts the segment growth
- 5. Global Immunosuppressive Drugs Market Size Forecast 2020-2030 by Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 5.1. Market Overview
- 5.2. Autoimmune Diseases
- 5.2.1. Rising adoption of biologics for the treatment of autoimmune diseases
- 5.2.2. Rheumatoid Arthritis
- 5.2.2.1. Prevalence of rheumatoid arthritis is the high in developed countries
- 5.2.3. Multiple Sclerosis
- 5.2.3.1. Immunosuppressive drugs are most successful in stages of MS with an inflammatory component
- 5.2.4. Psoriasis
- 5.2.4.1. Patients with moderate-to-severe psoriasis are commonly treated with systemic immunosuppressants
- 5.2.5. Crohn’s Disease
- 5.2.5.1. Some common immunosuppressive drugs used for the treatment of Crohn's disease are azathioprine (Imuran), mercaptopurine (Purinethol), cyclosporine (Gengraf, Neoral, Sandimmune), and methotrexate
- 5.2.6. Other Autoimmune Diseases
- 5.2.6.1. Rising incidence of other autoimmune diseases projected to boost the segment growth
- 5.3. Organ Transplant
- 5.3.1. A large number of transplantation procedures were reported in developed regions such as the U.S., U.K., Germany, and France
- 6. Global Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 by Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 6.1. Market Overview
- 6.1.1. Oral Drugs
- 6.1.1.1. The largest revenue grossing segment in 2019
- 6.1.2. Intravenous Drugs
- 6.1.2.1. Mounting adoption for the treatment of patients with organ transplant
- 7. Global Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 by Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 7.1. Market Overview
- 7.1.1. Hospital Pharmacies
- 7.1.1.1. Accounted for the largest revenue share in 2019
- 7.1.2. Retail Pharmacies
- 7.1.2.1. One of the most preferred channel of distribution
- 7.1.3. Online Pharmacies
- 7.1.3.1. Provide better pricing, with increased access, convenience, and greater privacy for users.
- 8. Immunosuppressive Drugs: R&D Pipeline Analysis, 2020
- 8.1. R&D Pipeline Overview
- 8.1.1. Cosentyx (secukinumab)
- 8.1.1.1. A fully human injectable monoclonal antibody
- 8.1.2. RINVOQ (upadacitinib)
- 8.1.2.1. It is an investigational oral JAK1-selective inhibitor
- 8.1.3. SKYRIZI (risankizumab)
- 8.1.3.1. EC granted marketing authorization for SKYRIZI for moderate to severe plaque psoriasis
- 8.1.4. RG7845 (GDC-0853)
- 8.1.4.1. A novel tyrosine kinase (BTK) inhibitor
- 8.1.5. RG7413 (etrolizumab)
- 8.1.5.1. Clinical trials are underway to test etrolizumab in ulcerative colitis and Crohn's disease
- 8.1.6. Benlysta + Rituxan
- 8.1.6.1. Clinical study to investigates Benlysta in combination with rituximab in adult patients with SLE
- 8.1.7. STELARA (ustekinumab)
- 8.1.7.1. Showed positive outcomes as maintenance therapy in adults patients with moderate to severe ulcerative colitis
- 8.1.8. TREMFYA (guselkumab)
- 8.1.8.1. New clinical study data from two Phase III trials
- 8.1.9. OTEZLA (apremilast)
- 8.1.9.1. Positive results from the Phase III trial
- 8.1.10. NULOJIX (belatacept)
- 8.1.10.1. Can help patients with kidney transplants safely and effectively without the long-term negative side effects
- 9. North America Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 9.1. Market Overview
- 9.2. North America Immunosuppressive Drugs Market Size and Forecast by Country
- 9.2.1. The Largest Revenue Grossing Region
- 9.3. North America Immunosuppressive Drugs Market Size and Forecast by Drug Class
- 9.3.1. Antibodies Sub-Segment Will Dominate The Market
- 9.4. North America Immunosuppressive Drugs Market Size and Forecast by Application
- 9.4.1. Organ Transplant Segment Will Witness Fastest Growth Rate
- 9.5. North America Immunosuppressive Drugs Market Size and Forecast by Route of Administration
- 9.5.1. Increasing Number of Approvals For Oral Drugs
- 9.6. North America Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
- 9.6.1. Online Pharmacies Segment is Anticipated to Witness Highest CAGR
- 9.7. U.S. Immunosuppressive Drugs Market
- 9.7.1. Presence of Leading Vendors
- 9.7.2. Rise in the Number of Drug Approvals
- 9.8. Canada Immunosuppressive Drugs Market
- 9.8.1. High Investment in Drug R&D
- 9.8.2. Growing Number of Organ Transplant Procedures
- 10. Europe Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 10.1. Market Overview
- 10.2. Europe Immunosuppressive Drugs Market Size and Forecast by Country
- 10.2.1. The Second Largest Regional Market
- 10.3. Europe Immunosuppressive Drugs Market Size and Forecast by Drug Class
- 10.3.1. Calcineurin Inhibitor Segment Expected to Grow at Lucrative Rate
- 10.4. Europe Immunosuppressive Drugs Market Size and Forecast by Application
- 10.4.1. Easy Access to Advanced Immunosuppressive Drugs for the Treatment of Autoimmune Diseases
- 10.5. Europe Immunosuppressive Drugs Market Size and Forecast by Route of Administration
- 10.5.1. High Adoption of Oral Drugs
- 10.6. Europe Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
- 10.6.1. Growing Preference for Online Pharmacies
- 10.7. UK Immunosuppressive Drugs Market
- 10.7.1. A Hub for Advanced Drugs Development and Production
- 10.7.2. Increasing Prevalence of Autoimmune Diseases
- 10.8. Germany Immunosuppressive Drugs Market
- 10.8.1. Strong Funding for Healthcare
- 10.8.2. Universal Health Systems
- 10.9. France Immunosuppressive Drugs Market
- 10.9.1. Increasing Number of Organ Transplant Procedures
- 10.9.2. High Quality Renowned Medical Care With Innovation
- 10.10. Italy Immunosuppressive Drugs Market
- 10.10.1. Disinvestment, Delocalization, and Restructuring of Italian Pharmaceutical Companies
- 10.10.2. A Large Pharmaceutical Manufacturing Hub
- 10.11. Spain Immunosuppressive Drugs Market
- 10.11.1. Presence of Innovation Infrastructure and Government Funding
- 10.11.2. Availability of Highly Skilled Workforce
- 10.12. Russia Immunosuppressive Drugs Market
- 10.12.1. An Attractive Market for Any Industry Looking to Expand Within the Country
- 10.12.2. Government Support for Development of the Healthcare Sector
- 10.13. Rest of Europe Immunosuppressive Drugs Market
- 10.13.1. The EU Action Plan on the Organ Donation and Transplantation
- 10.13.2. Rising Incidences of Autoimmune Diseases
- 11. Asia Pacific Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 11.1. Market Overview
- 11.2. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Country
- 11.2.1. Asia Pacific market expected to grow at fastest rate
- 11.3. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Drug Class
- 11.3.1. mTOR Inhibitor segment projected to grow at significant CAGR during 2020-2030
- 11.4. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Application
- 11.4.1. Rising incidence of organ failure and autoimmune diseases in Asia Pacific
- 11.5. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Route of Administration
- 11.5.1. Rising adoption of injectable drugs
- 11.6. Asia Pacific Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
- 11.6.1. Rapidly developing economies, skilled workers, and technological innovation
- 11.7. Japan Immunosuppressive Drugs Market
- 11.7.1. Presence of Leading Pharmaceutical Companies
- 11.7.2. High Investment in R&D
- 11.8. China Immunosuppressive Drugs Market
- 11.8.1. Government Support to Strengthen the Healthcare Infrastructure
- 11.8.2. Presence of Large Geriatric Population
- 11.9. India Immunosuppressive Drugs Market
- 11.9.1. Availability of Large Trained Workforce
- 11.9.2. Growing Technical Capabilities
- 11.10. Australia Immunosuppressive Drugs Market
- 11.10.1. Australia Has a Rich Research Environment Coupled with Highly Experienced Researchers and Professionals
- 11.10.2. Excellent Health Care Infrastructure
- 11.11. Rest of Asia Pacific Immunosuppressive Drugs Market
- 11.11.1. Increasing Incidence of Autoimmune and Inflammatory Diseases
- 11.11.2. Rising Disposable Income
- 12. Latin America Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 12.1. Market Overview
- 12.2. Latin America Immunosuppressive Drugs Market Size and Forecast by Country
- 12.2.1. Developing healthcare infrastructure
- 12.3. Latin America Immunosuppressive Drugs Market Size and Forecast by Drug Class
- 12.3.1. Antibodies was the largest revenue grossing subsegment
- 12.4. Latin America Immunosuppressive Drugs Market Size and Forecast by Application
- 12.4.1. Organ transplant segment will witness fastest growth rate
- 12.5. Latin America Immunosuppressive Drugs Market Size and Forecast by Route of Administration
- 12.5.1. Oral Drugs segment projected to dominate the market during the forecast period 2020-2030
- 12.6. Latin America Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
- 12.6.1. Retail pharmacies segment accounted for significant revenue share
- 12.7. Brazil Immunosuppressive Drugs Market
- 12.7.1.1. Growing Disposable Income
- 12.7.1.2. Rapidly Improving Healthcare Infrastructure
- 12.8. Mexico Immunosuppressive Drugs Market
- 12.8.1.1. Affordable Treatments Option for Organ Transplant
- 12.8.1.2. Government Initiatives That Aim at Providing Better Healthcare Facilities
- 12.9. Rest of Latin America Immunosuppressive Drugs Market
- 12.9.1.1. Growing Burden of Autoimmune Diseases
- 12.9.1.2. Availability of Skilled and Inexpensive Workforce
- 13. MEA Immunosuppressive Drugs Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
- 13.1. Market Overview
- 13.2. MEA Immunosuppressive Drugs Market Size and Forecast by Country
- 13.2.1. Developing Healthcare Infrastructure
- 13.3. MEA Immunosuppressive Drugs Market Size and Forecast by Drug Class
- 13.3.1. Corticosteroids Segment Expected to Show Lucrative Growth Rate
- 13.4. MEA Immunosuppressive Drugs Market Size and Forecast by Application
- 13.4.1. Organ Transplant Segment Will Witness Fastest Growth Rate
- 13.5. MEA Immunosuppressive Drugs Market Size and Forecast by Route of Administration
- 13.5.1. Rising Adoption of Oral Drugs For the Treatment of Patients With Organ Transplant
- 13.6. MEA Immunosuppressive Drugs Market Size and Forecast by Distribution Channel
- 13.6.1. Hospital Pharmacies Dominated the Market
- 13.7. Saudi Arabia Immunosuppressive Drugs Market
- 13.7.1.1. Presence of huge growth opportunities
- 13.7.1.2. Introduction of the Medical Aid Schemes Bill, National Health Insurance Bill, and introduction of new regulator for medicines
- 13.8. South Africa Immunosuppressive Drugs Market
- 13.8.1.1. Rising focus of pharmaceutical & biotechnology companies in this region
- 13.8.1.2. An emerging economy
- 13.9. Rest of MEA Immunosuppressive Drugs Market
- 13.9.1.1. Developing Healthcare Infrastructure
- 13.9.1.2. Rising Prevalence of Chronic Autoimmune Diseases
- 14. Companies in the Immunosuppressive Drugs Market
- 14.1. F. Hoffmann-La Roche AG
- 14.1.1. Company Snapshot
- 14.1.2. Company Overview
- 14.1.3. Financial Performance (2015-2020)
- 14.1.3.1. Net Revenue ($mn), 2015-2019
- 14.1.3.2. Segment Revenue Share, 2019
- 14.1.3.3. Geographical Revenue, 2019
- 14.1.4. Product Offerings
- 14.1.5. Recent Initiatives (2017-2020)
- 14.2. GlaxoSmithKline Plc
- 14.2.1. Company Snapshot
- 14.2.2. Company Overview
- 14.2.3. Financial Performance (2015-2019)
- 14.2.3.1. Net Revenue
- 14.2.3.2. Segment Revenue Share, 2019
- 14.2.3.3. Geographical Revenue, 2019
- 14.2.4. Product Offerings
- 14.2.5. Recent Initiatives (2017-2020)
- 14.3. Johnson and Johnson
- 14.3.1. Company Snapshot
- 14.3.2. Company Overview
- 14.3.3. Financial Performance (2015-2019)
- 14.3.3.1. Net Revenue
- 14.3.3.2. Segment Revenue Share, 2019
- 14.3.3.3. Geographical Revenue, 2019
- 14.3.4. Product Offerings
- 14.3.5. Recent Initiatives (2017-2020)
- 14.4. Novartis AG
- 14.4.1. Company Snapshot
- 14.4.2. Company Overview
- 14.4.3. Financial Performance (2015-2019)
- 14.4.3.1. Net Revenue
- 14.4.3.2. Segment Revenue Share, 2019
- 14.4.3.3. Geographical Revenue, 2019
- 14.4.4. Product Offerings
- 14.4.5. Recent Initiatives (2017-2020)
- 14.5. Sanofi SA
- 14.5.1. Company Snapshot
- 14.5.2. Company Overview
- 14.5.3. Financial Performance (2015-2019)
- 14.5.3.1. Net Revenue
- 14.5.3.2. Segment Revenue Share, 2019
- 14.5.3.3. Geographical Revenue, 2019
- 14.5.4. Product Offerings
- 14.5.5. Recent Initiatives (2017-2020)
- 14.6. Eli Lilly and Company
- 14.6.1. Company Snapshot
- 14.6.2. Company Overview
- 14.6.3. Financial Performance (2015-2019)
- 14.6.3.1. Net Revenue
- 14.6.3.2. Segment Revenue Share, 2019
- 14.6.3.3. Geographical Revenue, 2019
- 14.6.4. Product Offerings
- 14.6.5. Recent Initiatives (2017-2020)
- 14.7. AbbVie Inc.
- 14.7.1. Company Snapshot
- 14.7.2. Company Overview
- 14.7.3. Financial Performance (2015-2019)
- 14.7.3.1. Net Revenue
- 14.7.3.2. Segment Revenue Share, 2019
- 14.7.3.3. Geographical Revenue, 2019
- 14.7.4. Product Offerings
- 14.7.5. Recent Initiatives (2017-2020)
- 14.8. Amgen Inc.
- 14.8.1. Company Snapshot
- 14.8.2. Company Overview
- 14.8.3. Financial Performance (2015-2019)
- 14.8.3.1. Net Revenue
- 14.8.3.2. Segment Revenue Share, 2019
- 14.8.3.3. Geographical Revenue, 2019
- 14.8.4. Product Offerings
- 14.8.5. Recent Initiatives (2017-2020)
- 14.9. Bristol Myers Squibb Company
- 14.9.1. Company Snapshot
- 14.9.2. Company Overview
- 14.9.3. Financial Performance (2015-2019)
- 14.9.3.1. Net Revenue
- 14.9.3.2. Segment Revenue Share, 2019
- 14.9.3.3. Geographical Revenue, 2019
- 14.9.4. Product Offerings
- 14.9.5. Recent Initiatives (2017-2020)
- 14.10. Astellas Pharma Inc.
- 14.10.1. Company Snapshot
- 14.10.2. Company Overview
- 14.10.3. Financial Performance (2015-2019)
- 14.10.3.1. Net Revenue
- 14.10.3.2. Segment Revenue Share, 2019
- 14.10.3.3. Geographical Revenue, 2019
- 14.10.4. Product Offerings
- 14.11. Other Notable Players
- 15. Conclusion
- 16. Glossary
- List of Tables
- Table 1 Global Immunosuppressive Drugs Market, 2020-2030 (US$ billion, CAGR %)
- Table 2 Prevalence of Autoimmune Diseases, 2020
- Table 3 Prevalence of Autoimmune Diseases, 2020
- Table 4 Immunosuppressant Drugs: Average Cost per Set Period of Time by Dose
- Table 5 Total R&D Investment by Leading Players
- Table 6 Major M&A and Collaborations: Immunosuppressive Drugs Market
- Table 7 Global Immunosuppressive Drugs Market Forecast by Drug Class, 2020-2030 (US$ billion, AGR %, CAGR %)
- Table 8 “V” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 9 “U” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 10 “W” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 11 “L” Shaped Recovery: Global Immunosuppressive Drugs Market, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 12 Global Immunosuppressive Drugs Market for Antibodies Segment: Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 13 “V” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 14 “U” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 15 “W” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 16 “L” Shaped Recovery: Global Immunosuppressive Drugs Market for Antibodies Segment, Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR%)
- Table 17 Global Immunosuppressive Drugs Market for Calcineurin Inhibitor Segment: Revenue Forecast 2020-2030 (US$ billion, AGR%, CAGR %)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook